'I can get more time': Breast cancer patient finds out she can get life extending drug
Summary
Patients in England with a certain type of advanced breast cancer can now get a new drug called Enhertu on the NHS. This drug can help them live nearly seven months longer on average.Key Facts
- Enhertu is available to patients with HER2-low metastatic breast cancer in England.
- The drug can extend life by about seven months on average.
- Women in Scotland and 26 other European countries have had NHS access to Enhertu since 2023.
- Wales is expected to make Enhertu available soon, but it is not yet approved in Northern Ireland.
- Kate Wills, a 51-year-old patient with advanced breast cancer, expressed relief and hope about the drug being available.
- HER2-low breast cancer means the cancer cells have low levels of a protein called HER2, which affects treatment options.
- The NHS approval means doctors can now prescribe Enhertu to eligible patients in England.
- This drug is seen as a significant development for patients with incurable breast cancer to improve survival time.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.